RPI ID: 2021-001-401
Innovation Summary: A therapeutic composition combines multiple protein inhibitors to target SARS-CoV-2 replication pathways. The method leverages synergistic interactions between inhibitors to enhance antiviral efficacy. It includes formulations for systemic and localized delivery, and supports adaptation to emerging variants. The approach is validated through in vitro and in vivo studies.
Challenges / Opportunities: Single-agent therapies often face resistance and limited efficacy against evolving viral strains. This invention addresses those challenges by combining inhibitors with complementary mechanisms. It opens opportunities for broad-spectrum antiviral development and rapid response to future outbreaks. The method supports integration into existing treatment protocols.
Key Benefits / Advantages: ✔ Synergistic antiviral activity ✔ Multi-pathway inhibition ✔ Variant adaptability ✔ Systemic and localized delivery ✔ Clinically validated
Applications: • COVID-19 treatment • Antiviral drug development • Pandemic response
Keywords: #SARSCoV2 #antiviraltherapy #proteininhibitors #drugformulation #pandemicresponse #biopharma
Intellectual Property: US Application 18/030366 US20230372381A1 filed 05-Apr-2023